ArticlePhysics and imaging in radiation oncology2023
Risk of second primary cancer from proton arc therapy of pediatric brain tumors.
Article in Physics and imaging in radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Reducing the dose delivered to major intracranial blood vessels in brain radiotherapy using spot-scanning proton arc therapy.Journal of applied clinical medical physics · 2026Article
- Particle Arc Therapy in Cancer Radiotherapy: A Scoping Review of Feasibility and Dosimetric Evidence.Cancers · 2026Review
- Proton arc therapy and associated improvements in quality-adjusted life expectancy for head-and-neck cancer patients compared to volumetric modulated arc therapy and intensity-modulated proton therapy.Physics in medicine and biology · 2025Article
- Automated Planning for Bias-Free Validation of Discrete Proton Arc Therapy for Oropharyngeal Cancer.International journal of particle therapy · 2025Article
- Development and dosimetric verification of static SHArc: Step-and-shoot carbon ion arc therapy for LETMedical physics · 2025Article
- Dosimetric comparison of intensity-modulated proton therapy and proton arc therapy for pediatric ependymoma.Acta oncologica (Stockholm, Sweden) · 2025Article
- New guidelines and recommendations to advance treatment planning in proton therapy.Physics and imaging in radiation oncology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction were applied in five cases to compare volumetric modulated arc therapy (VMAT), intensity modulated proton therapy (IMPT) and PAT surrogate plans. The PAT integral dose was reduced by a median of 29% compared to VMAT, and 17% compared to IMPT. For both models, the estimated SPC risks were consistently the lowest for PAT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.